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Objdw. This study was underiaken to cbmxterize tbe out- 
max af survivors of ventricul~l tibnllstim wttb no or ninhnsl 
structural heart divpse who recdved aa impbmtable cardk~erter- 
deabrillntor. 
Background. The prognosis among survivon cd ventrlrulnr 
fibrillalioo with ndnirnrl or no structural card&c abaormalI(ies 
remains unclear. Since tk advent of implantable cardiovevkr- 
deftbrtllators, thh question takes on added imaortance. 
Melhods. ihis llhnter retmsp&ive stady~pmvidd informa. 
60” oa 24 survivors of ventricular fibrillation (mean axe 42 yeam) 
with minbd or 110 structurat abnormdtties who w&e &ted 
with an implantable cmdioverter~defibrllla(or. 
Reruf~s. Vcntrtcular tacbynrrhythmias (polymorphic in all but 
one patient) were induced during bsrellne pmarammed stlmula. 
tlan in 39% of patirnls. Daring a median 36.6.mmttb fallow.ap 
period atler implantable cardiovcrter&llbrlllator Implaatatlw, 
(hove ware 110 cardiac deaths and two aomxrdiac death;. 98 
teen ~&teats experien~J 36 shock qisodrn (t&l MI shacks). 
Tbe majmily of shacks were da&ted as “lmkterminatc”; one 
ptient received 47 “sp,&ms” ~bocks during (IOC shock ephcde 
and each d an~r pstlmb receJved one “appmpvlate” shock. 
Vealricnlar urhyihmlas were not indudbk ln any oftbae Ner 
four ptknts. 
(J Am Cdl Cardial 1993;21:14&W.2) 
Structural heart disease is absent in up to 5% of survivors of 
oot-of-hospital cardiac arrest (I ,2). Moreover, 10% to 17% of 
forensic examinations fail to reveal the cause of sudden death 
in victims Younger than 45 years of age O-5). Compared with 
data on survivors of cardiac arest with significant identifiable 
structural heart disem. considerably less is known about the 
impact of therapeutic options and prognosis in survivors of 
cardiac arrest who have minimal o( no structural heart disease. 
Published re~rts (6.7) of viclims of “idiwathic ventricular 
fibrillation” have sag&ted a good pq&is in survivors 
treated with class IA antiarrhYthmic agents. However, the 
reported number of such patients has been limited, aad little is 
known about the results of alternative therapies. 
Because of the relative rarity of such patients with 
cardiac arrest and minimal or no structural hean disease, we 
retrospectively pooled data from IO institutions to better 
define the clinical characteristics and recurrent arrhythmic 
risk among those patients whose primary treatment was an 
implantable cardioverter-defibrillator. The outcome of such 
treatment in this patient subset has never ken systemati- 
cally studied; moreover, the close follow-up that patients 
undergo after cardioverter.defibrilIator imDlantation facili- 
tated long-term tracking of possible cardiac events. 
Study pa&&. This IQcenter retrospective study included 
28 p~tie”ts who had received a” implantable cardiovertcr- 
defibrillator system between February 1983 and November 
19% within ! to 25 weeks after cardiac arrest due to dccu- 
mented ventricular fibrillation in the absence of significant 
st~ctural heart disease. Patients were entered into the study if 
they met the following inclusion criteria: 1) normal electroivte 
and xid-base status~after cardiac arrest, 2) no hiztou-of 
alcohol or drug abuse, 3) zhseocr: of antiarrhythmic drugs 
before cardiac arrest, 4) left ventricular eiection b-action a%%. 
and 5) nomtal right vsotricular contractility. Exclusion criteria 
were 1) significant lschimic heart disease (aSO% coronary 
artery lumen stenosis or ischemic response to ac exrcir~ test. 
or both), 2) coronary artery spasm by history orekctrocan:io- 
gram (ECG) (ergonovine provocation was not mutinely per- 
formed, but results were negative in the six patients in whom it 
was performed), 3) signilicant myocardial hwrimpby (I& 
venthcttlar wall thick& >I3 &or left vent&“lar hg&ro- 
phy on the EC@. 4) siinilicattt valvular heart disease (includ- 
ing mitral valve prolapse with more than trace mitral repurgj- 
&ion). and 5) &o&d QT intewd iiunected QT interval 
>440 md after cardiac arrest. 
D&gnas(k shtdies and treratme”t. The pres rce of isch- 
emit heart disease was assessed by cardiac _athcterization 
or exercise testing. or both, with or without thallium imag- 
ing. Nonspecific ST and T wave abnomtalities alone on a 
rest ECG did not disqualiij patients from entry into the 
study provided that there was no associated significant 
coronary or st~ctural hwt disease as assessed by the 
aforementioned criteria. 
Ventricular function was assessed by one of the follow- 
ing: contrast ventriculwiaphy, echocardioawhy or nuclear 
imaging (for example. multiple-gate acqutsdton scan 
IMUGAI. radionuclide aneioeraohv). Electroohvsioloeic 
studies were performed in ~l-$~iie&s. “sing e&“tio&d 
techniques. During programmed electrical stimulation, up to 
three (24 patients, IO centers) or four (I patient, I center) 
ventricular extrastimuli were delivered to the right ventric- 
ular apex (28 patients) and right ventricular out&w tract (23 
~&ents). A left ventricular site was used in six patients (five 
centers): in three patients (one in each of three centerst, the 
maximal number of extrastimuli used was not reported. I” 
nine centers. arrhythmia induction was reattempted during 
isoproterenol or epinephrine infusion when no arrhythmias 
were inducible at baseline study in 14 (56%) of 25 patients for 
whom these data were available. 
Impla”table cardioverter-deBbrUlal”r implantntmr. 4 
thnncotomy approach was used in all patients to place the 
implantable cardioverter.+tibriUator patches. Epiardiai 
set&g electrodes were placed in 21 patients, and a Irano- 
ve”“us electrode was used in 1 patient. The de&b&&g 
electrodes consisted of hio patches in 27 patients and a 
coil-patch co”&ur%io” in one patie”:. Delbrillation thresh. 
olds raged from 4 to 25 3 (mean 14). 
The followinc cardioverterdefibrU!ztor eenerator models 
were implanted: lntec AID (Intec Sys:e& in six patients. 
Ventak IS00 series (Cardiac Pacemakers. Inc.) in 20 “atients 
and Ventak SOtI series in two patients. 
Device rate cutoff (n = 27l ranged from I51 to 204 
beatsimi” (mea” 182); device rates were I51 to 155 beats/min 
in only two patients, and hi&her io the remaining patients. 
Energy deliver/ was set from 25 to 32 J. The probability 
density function was osed in four patients. 
Follow-up. After implantation, each patient was typically 
seen every 2 to 3 months in year 1. subsequently every other 
month foor 6 months and the” monthly until generator re- 
placement. Patients were instructed to notify their physi- 
cians as 500” “s possible after eceiving a shock. They were 
questioner! in detail about symptoms preceding and bnmedi- 
atelk following repOrted shocks. 
Detinitionr. The following definitions were used. 
Susrained ventricular tachycardia = ventricular tachy- 
cardi” lasting 230 s or requiring temtination beforehand 
because of hemodyntatic compromise. 
Nonsusrained ventricular tachycordia = Ten or “tore 
beats and 530 s of ventricular tachycwdia that terminated 
spo”ta”eously. 
Sadden cardiac de&h = u”exPected cardiac death within 
I h of the onset of symptoms or unwitnessed in a previously 
stable patient. 
Shock episoL = a shock or series of shocks delivered for 
a single arrhythmic event. after which the patient was free of 
symptoms and shocks for a10 min (8). 
Approprinfe shock = a shock that WBS delivered during a 
shock episode and I) preceded by symptoms of severe 
light-headedness, presyncope or symope and followed by 
immediate re!icf fmm there symptoms, or 2) witnessed while 
the patient was on a cardiac monitor and documented to he 
associated with sustained ventricular tachycatdia orventrk- 
alar fibrillation (8). 
Spurious skock = a shock that wa I) delivered while the 
patient was on a card& monitor. and 2) doettmented not to 
be associated with sustained ventricttlar tachycardia or 
ventricul”r tibrillatkm (IO). 
lndererminate shock = a shock that occurred during a 
shock episode that could not be classi6ed as either appro- 
priate or spurious by our definitions (8). 
staw Malysis. Data are expressed as “lea” value * I 
SD. Comparison between groups was performed using the I 
test for unpaired data, chi-square analysis or Fisher exact 
test and, where appropriate, analysis of viuiance. Media” 
time to outcome (for example. survival or implantable 
cardiovencr-detibrillillstor shock) was estimated wing the 
Kaplan-M&r method of actuarial analysis. A p value < 0.0s 
was considered signjlicant. 
Results 
Clinical ehamcteristi~ fiWe 1). Clinical characteristics 
of the 28 patients are summarized in Table 1. There were IS 
men and 13 women, with a mean age of 42 + I4 years. Two 
patients gave a history of ptior cardiac arrest, and two patients 
had experienced a previous episode of syncape. Several pa- 
tients had other medical problems, including hypertension, 
diabetes mellitus, chronic obstructive pulmonary disease, 
treated ovarian carcinoma, intlammatwy polyneuwpathy and 
treated inactive sarcoidosis with no evidence of cardiac in- 
volvement (nomml ECG and echwrd&mm and absence of 
conduction abnomtulities at electrophysiologic study). Moat 
patients were either at rest or engaged in mild exertion at the 
time of cardiac arrest. 
Twelve-lead ECGs were normal in 7 (26%) of27 patients. 
Abnornmlities noted in the other 20 patients consisted pri- 
mwily of ST-T wave abnormalities and/or conduction dis- 
turbances (first degree atrioventricular block [one patient], 
incomplete or complete right bundle branch block [four 
patients] and left bundle branch block [two patientsI). No 
patient developed ventricular tachycardia during exercise. 
Rem& of wxramm al ventricular stJmulatioo. Results of 
baseline (bef~~-~dioverter-defibrillator implantation) pro- 
grammed ventricular stimulation performed in the absence 
of antianhythmic drugs are summarized in Figure 1. Almost 
two thirds d the patients bad no inducible ventricular 
tacbyarrhythmias. Slightly more than one third had inducible 
axhythmias, with ventricular fibrillation and ventricular 
tachywdia each comprising -50% of these arrhythmias. 
Sustained ventricular fibrillation was induced with triple 
extrastimuli in all five watients. three of wham also bad 
inducible nonsustained &uric& tachycardia. Ventricular 
fibrillation was no longer inducible after antiarrhythmic 
therapy in two of the five patients who received procain- 
amide. Multiple dilferent antiarrbythmic agents failed to 
suppress ventricular tachycardia inducibility in the patients 
in whom sustained monomorphic ventricular tachycardia 
was induced at baseline study. 
Among patients in whom ventricular fibrillation was not 
inducible, induced sustained ventricular tachycardia was 
wlymomhic (cycle length 2.50 ms) in one patient and mono- 
morphic-(left bundle branch block/right &erior axis) and 
rapid (cycle length 210 ms) in another patient. Nonsustained 
polymorphic ventricular tachycardia or ventricular flutter, 
induced in four patients, ranged from 9 to 40 beats and was 
nonreproducible iu three patients. One patient experienced 
three spontaneous. self-terminating 30-s symptomatic epi- 
scdesofventricularflutter(cyclelength2Mms)th+dayafter 
an elecuopbysiologic study demonstrated no inducible ven- 
tricular tachywdia or ventricular fibrillation. 
Coaeomftmt~fTabk21. Thetwonatientswbohad . . 
inducible sustained vcntric& tachycardia wex treated 
unsuccessfully with several antiarrhythmic agents (ami+ 
darone ph13 procainamide in one and pwainamidc, mexi- 
letine, tkcainide and amiodarone in the other). In 16 patients 
treated with implantation of a wdioverterdelibrillator, the 
discharge regimen included various cardiwctive media 
tions (Table 2). 
suwivalandhnplratpblccardbverter4eft~torabofir. 
The 28 palients were followed up for a median of 30.6 
months (range 0.7 to 91.4) after receiving an implantable 
cardiovertcrdcfibrillator. Cumulative actuarial survival af- 
ter implantation of the device is shown in Figure 2. Thexc 
were no sudden or nonsudden cardiac deaths durira follow- 
massive stroke, the other of mesenteric ischemia. 
Sixteen patients (57%) experienced 36 shock episodes 
and a total of 88 shocks; six of these patients had >I shack 
episode (range 2 to 7). The cumulative freedom from shocks 
after cardioverterdetibrillator implantation is shown in Fig- 
ure 3. Survival free of any shack or free of an appropriate 
shock at 2 years was 59% and 82%, respectively, and 54% 
and 82% at 3 years after cardiovmterdaibiitlator implanta. 
tion. For all patients, the esdmated median time to a lirst 
shack was 30.5 months; for the 16 patients who received 
shocks, the median time to a tint shock was 13.1 months. 
Symptoms immediately preceditw shocks are summa- 
rized in Figure 4. Patients v&e asymptomatic immediately 
before 73% of shock e&&s. One of the folIowine SWIIP 
tams preceded 3% of’ shock episodes: palpitation, &it- 
headedness, aunt or throat fullness and presyncope. Symp 
tom status was utdmown in one patient. 
The physical activity level immediately before shock 
episodes is summarized in Figwe 5. Vigor&s exercise (for 
example, bicycling, itinp;. swimmina) immediatel’ PR- 
ceded just o&r 50% of shock episcd&, whereas p&&s 
were sedentary or engaged in mild activity before >40% of 
shock episodes. 
A total offwr shocks defined as appropriate were deliv- 
ered, one to each of four patients. three of whom were 
presyncopal and one of whom was light-headed immediately 
F@eZ. Cumulative survival free from cardiac death and &cause 
mmtality during the 1st 36 months atIer implantation (Post.lmpla”t) 
of the cardioverter-defibrittator. Median follow-up time was 10.6 
months (i-we 0.7 to 91.4). The numben (N, at the b+ttmn o( tba 
gmpb indicate the number of patients available for amlysis at the 
respective Cmonth paicds. 
t&xx the shock. The four a~~mpriate shocks ofcurred at 
11.4, 14.7, 19.7 and 23.l‘&~ths after cardioverter- 
defibrillator implantation. None of these patients had induc- 
ible ventricular tachycardia or ventricular fibrillation with 
programmed ventricular stimulation. One patient received 
47 shocks defined as swious durina one shock &ode: 
monitoring at that time bwumented a&d tibrillatio~ with a 
rapid ventricular response. This was the largest number of 
shocks experienced by any patient in our cohort. The 
remaining 3 I shock episcdes (37 shocks) were categorized as 
indeterminate. The majority (81%) of these were preceded 
by vigorous or mild physical activity (IS and 7 shock 
episodes, respectively). Ftuthemtore, these 31 patients were 
asymptomatic immediately before 26 (84%) of the 31 shock 
episodes, whereas the remaining 5 patients experienced 
palpitation (n = 3). fullness in the thmat (n = I) or aura (tt = 
Ftgure 3. Cumulative survival fmm implantable cardioverter- 
defibrillator shwks during the 1st 36 months at’ter implantation 
(Post-lmplam~. Median follow-up time v/as 30.6 monrhs (ranpe 0.7 
to 91.4). The numbers (Nl at the battwa d tbc graph indicate the 
“umber of patients availab!e for analysis ~1 the nqxctive dmonlb 
peliadr. 
Ftgorr 4. Symptoms immediately before implantable cardiovertcr- 
defibrillator shock episodes (shown as percent of total shwk c;li- 
I). During follow-up, rate matsensing of the epicardial leads 
in one patient resulted in placement of an endocardial 
sensing lead. Although such a sensing problem strongly 
suggests that the six shocks that this patient received were 
“spurious,” they were nevertheless labeled indeterminate, 
in keeping with the prospectively chosen ctiteria. 
None of the following factors were associated with oc- 
currence of patient shocks: age, gender, left ventricular 
ejection fraction, prior cardiac arrest, activity level at the 
time of cardiac atTest, antiarrhythmic therapy at hospital 
discharge, inducibility of ventricular tachycardia. ventricu- 
lar fibrillation and nonsustained ventricular tachycardia dur- 
ing programmed ventricular stimulation. 
Devtfe follow.up. During the follow-up period, a total pf 
19 implantable cardioverterdefibriltator generators were re- 
placed in I I patients in whom the indication was expected 
battery end of life. There were no infections that necessi- 
tated generator explantation. Multiple (two to four) genera- 
tor replacements were performed in four patients. In the 
patients for whom such data were available, first-time gen- 
erator replacement occurred from I9 to 37.5 months after 
initial implantation. 
Discussion 
Our study represents the largest reported experience of 
survivors of cardiac arrest in the absence of significant 
structural heart disease, as well as the iirst systematic stttdy 
of implantable cardioverter-defibrillator therapy in such pa- 
tients. The main findings are I) the 3.year survival rate with 
implantable cardioverter-defibrillator therapy is excellent; 
Figure 5. Level of physical activity immediately before implantable 
cardioverter-ddbrillator shock episodes (shown 88 percent of total 
shock episodes). 
2) neitherinducibilityofsustained ventriculartachycardiaor 
fibrillation (seen in only 39% of patients) nor other clinical 
variables were predictive of shock occurrence; 3) tbe occur- 
rence, albeit infrequent, of appropriate shocks, strongly 
suggests a potential risk of recurrent cardiac arrest in this 
group of patients. 
Demomwbte orolite. The ES raw and mean aae of our 
patients -& sin&r to those-of p&ems with idiopathic 
ventricular fibrillation oreviouslv reuorted (9). but YOUOIOF 
than those of patient; dyi_;g &ddenly in the s&i&of 
structural heart disease (IO). We also observed an almost 
equal (121) prom&on of men to women in oar study, 
which is considerably diierent from the 4:l to 7:l m& 
prepondemnce typically reported (I l-13) among adults with 
structural heart disease dying soddenly. 
FJeUmpbystdo$c f&dings. Despite the use of triple ex- 
trastimuli and, in some patients, stimulation at a IeR ventric- 
ular site or with isoprot&enol, ventricular tachyarrhythmiar 
were inducible in only 3% of our patients. Almost two 
thirds of these arrhythmias were sustained but consisted 
almost exclusively of ventricular fibrillation or polymorphic 
ventricular tachycardia. Sustained monomorphic ventricular 
tachycardia was encountered in only one patient. 
Our findings dither from the observed 69% average indoc- 
ibility rate of sustrdmd ventricular tachyarrhythmias urevi- 
ousl; reported (9) in patients with idiopathic v&icul~fibril- 
lotion, despite similarities in baseline clinicat descriptors. In 
one group’s experience (Belbaswn B. pMnal communica- 
tion). t&e anhythmias were inducible in I3 @7%) of 15 such 
been reported (9, to & sustained ventriculartachyar- 
rhythtnia in-&R ofpraicnts with idiopathic venbiadar fibril- 
lation for whom the mode of induction was s&tied. DhTer- 
eoces in ventticotar stimolation prutoals bo not readily 
Bccotmt for the discrepant indocibitity rates. The lower rate of 
inductionofventricular(achy~ardiawvcntricularfiin 
our series may relate to the biased nrdu~ of our stody gmup 
(that is. some tints with inducible sustained ventricular 
tachyanWhn& that were succ&~U~ supwesscd by a&r- 
rhythmic -med cation may not have u&&g& cafd&erter- 
delibtiUator imdantatkm). Howeva. a &iminav reoort (14) 
in a small se& tithoni this bias &&ns OUT &&ati& 
regarding programmed stimulation and suggests that our find- 
ings were mlt a” artifact of selection bias. 
None of the patients who received appropriate device 
shocks had inducible ventricular tachvcardia or ventricular 
fibrillation. This observation together-with oar etectrophys- 
iologic findings suggest both that programmed ventricular 
stimulation may not be us&ttl in guiding or gauging therapy 
in many survivors of ventricular fibrillation with minimal or 
no structural heart disease and that the absence of inducible 
ventricular tachyarrhythmias does not necessarily correlate 
with an event-free outcome. 
There were no car& deaths in our study patients during a 
median fotlow-up period of 30.6 months after cardioverter- 
defibrillator implantation. Two patients died of noncardiac 
causes. A etude (nonactuarial) I-year mortality rate of II% 
has been estimated from pooled repons (9) of 37 patients 
with idiopathic ventricular fibtilla:ion whose mean age was 
36 years. The 3.year survival rate with an implantable 
cardiowter-defibrillator in oat patients is excellent and 
superior to that reported (IO) in survivors of cardiac arrest 
with st~ctural heart disease treated similarly. 
Because there were no cardiac deaths in our patients, 
inferences about would-he sudden cardiac deaths could only be 
made by consideling appropriate shocks as surrogates for 
sudden cardiac death (that is. assumittg that death from cardiac 
arrest would have occurred in these patients had the device noi 
intervened). By this line of reasoning, the estimated Z-year 
actuarial sudden death rate in our patients would have been 
17.7% in the absence of implantable cwJiovenerdefibtillator 
therapy (Fe. 3). Such an ext&olatcd outcome is suppotted by 
the recent findings in a preliminaty report (IS). The small 
number of patieots (4 of 28) who received appropriate shocks. 
however. results in a relatively large 95% cootidence interval 
for our estimate (1% to 35%), thereby precluding B definitive 
compariwn with sudden death rates in patients with strttctuml 
heart disease. Despite this limitation. it is of interest that the 
exttz@ated Z-year sudden death rate in our oatients is simiiar 
to the tyear &mulative recurrent card& arrest rate for 
patients with structural heart disuse, repotted to range horn 
14% to 21% (1.16). 
The majority of shock episodes were categorized as 
indeterminate. and most patients (84%) were asymptomatic 
and en@ged in physical activity (81%) just before receiving 
stteh shocks. ‘II& finding suggests that sinus tachycardia, or 
perhaps atrial fibrillation with a twid ventricular reswnse. 
may have Irigged many nf thesehevice discharges. How- 
ever, the correctness of mis interpretation could not be 
definitively ascertained because paients were not monitored 
when the shocks were delivered. and their device could not 
provide specilic arrhythmia disclosures. 
Two of three patients cotwmitantly receiving amiodamne 
exeaienccd device shocks. As ptwiowly noted, various cliw 
ical ftiots were not found to be associated with delivew of 
sbwks to patients; these liodiogs may be due to inst&ient 
statistical mnver. aiven the relativelv smell size of the studv 
group. - .- 
Coanwkou witb preview studks. Previous reports con- 
eeming Wients with ventricular fibrillation that WIL* “idio- 
pathic” (8,9), io “adults without overt heart disease” (17) or 
in “ostensibly healthy prdients” (18) have been well summa- 
rized (9). Reports (6,14.15,17-22) have focused on experience 
wivl atttiMtyUtmic dm8 mana&tnmt in such patients, an 
approach tlxat has met with variable success. Our study is not 
readily compemble to these, however, lwuse the latter did 
not include implatttabk cardiaverterdefibti!laton as a major 
compaent of patient management. Fadier reports (17,23) 
providedfoUow-up btimmation inonlyone (17) oftwopaticnll 
treatedwith such devices. Subsequent oowinitial repott(24). 
hvo other prelimiwy cammunicatins (14.15) included a total 
of 18 pan ma with idiopathic veotricukr libtillatiott who re- 
ceived en implantable cardioverterdefibdl!ator, hut details and 
actuarial foUow-up data were not provided. Nevertheless, 
these preliminary studies support wrobservationswith regard 
to frequent absence of inducible sustained ventric&u tachyw 
rbytbmias in patients with idiopathic vetttcicular fibriUatioo and 
the view that maMgemerd with an impbate carZ;overter- 
defibrillator seems appropriate and can be lifesaving in many of 
these patients. 
Kudenchuk et al. (2.5) examined outcome in 43 survivors 
of cardiac arrest with preserved ventricular function and 
minimal coronary artery disease and reported a 5% actuarial 
recurrent cardiac arrest rate among patients whose ECG and 
ventricular wall motion were normal. However, study dif- 
ferences limit the ability to compare their study with ours. 
Study lbnilatbxa The fo!lowir,g study liitatioits desetve 
mention. I) Our group of survivors of ventricular fibiillation 
with no significant structural hean diiasx consisted entirely of 
those who received an implantable cardiiverterdefibriUator. 
Such an inclusion criterion may have introduced a selection 
bias imo the study group. 
2) Although significant structural heart disease was ex- 
cluded by conventional diagnostic techniques, occult ultra- 
structural abnormalities could not be dlnitivclv excluded as 
conttibutcrs to these patients’ arrhythmias @,26). Endo- 
myocardial biopsy specimens would have been required in 
all patients to exclude occult morphologic pathology and, 
even so. the clinical significance of histoloaic fmdinas ob- 
t&ted by such biopsies-&y be unccnaitt (2f28). A v.&ic- 
ular tachyarrbythmia can be the lint manifestation of right 
ventricular dyrplasia whose stt-.tctuml echocardiograpbic or 
angiographic features may become detectable only years 
after the arrhythmia. Nevertheless, one cannot truly diag- 
nose the entity until its sImcturd features &come detect- 
able. 
3) Because the lack of arrhythmia storage capabilities of 
the implantable cardioverterdctibrillator devices precluded 
d&it& arrhythmia diagnosis surrottndii ttn~nilored 
shocks. it was necessary IO desigwtc the shocks as apptw 
priate, spurious orindeterminate. Although some apparently 
appmpriate shocks may not have represented true sudden 
death equivalent events, it is also likely that some indeter- 
minate shocks actually represented aborted cardiac arrest 
(ZYI. Thus, the contention that some of our patients re- 
maitted at persistent risk of sudden death remains valid. 
4) Gur criteria did not allow us to definitivelv exclude 
silent myocardial ischemia do; to coronary artmy~spasm as 
a cause of cardiac arrest (30). However, this is a relatively 
rare event and would be an unlikely explanation in most. if 
any, of our patients, all cf whom had their index event at a 
time historically when etgonovine provocation was not 
b=elicved to be routinely indicated and was thus petformed in 
at& a mitwtity of patients. As we noted, however, the 
rest&s of such provocation were negative in our six patients 
who received ergooovine. Finally, our study was retrospec- 
live, similar to that cf other published reports concerning 
such patients without structural heart disease. 
Impticatiom. Acknowledaina the aforementioned study 
limitaiions, we have nonetheless observed important diiei- 
ences between patients with an implanted cardioverter- 
defibrillator who do not versus those who do have sigoiticaol 
structural heart disease (IO). For example, the former group 
of patients are typically younger and have a significantly 
belter prognosis, although a careftdly matched case-control 
study would be required to more precisely compare the 
outcome of survivors of ventricular ftbrillatiott in those with 
versus those without significant stmctuml heart disease. 
Results of implantable cardioverterdefibrillatortherapy may 
be markedly influenced by patient characteristics (for exam- 
ple, presence or absence of significant structural heart dis- 
ease). These considerations should prompt reawzssment ot 
the validity of analyzing mixed groups of implantable car- 
dioverter-defibrillator ecipients that include patients aith 
and without signiticant structural heart disease. 
Although cardiac arrest is uncommoo in patients without 
sianiticant structural hezut disease, it can have disastrous 
consequences for its victims. Extrapolations from device 
shock data in our study strongly imply that when these 
patients survive ventricular fibrillation, they remain at risk 
for sudden death. This conclusion is supported by recent 
areliinarv observations of others (14.15). Our findinas also 
&gest that implantable cardiovertdr-deibrillator therapy in 
patients with cardiac arrest in the absence of signiftcaot 
structural heart disease yiehis resuks at leaat comparable to 
those reported with class IA agents, with a probable advao- 
tage in patients who have no inducible ventricular tachycar- 
dia or ventricular fibrillation (6). 
In this relatively young group of patients, a more mean- 
ingful estimation of risk of sudden death with a given therapy 
will require longer-term follow-up of larger7 numbers ‘df 
patients, perhaps through an international registry. Addi- 
tionally, a prospective randomized clinical trial comparing 
device and nondevice therapy would appear reasonable, 
preferably using defibrillators with storage capabilities that 
would facilitate event analysis. 
